Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Urine-based test developed for early detection of head and neck tumors

Urine-based test developed for early detection of head and neck tumors

NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

NCCN 2024 Annual Conference focuses on practical applications for improving cancer care

Innovative cancer treatment approach yields promising results in pediatric patients

Innovative cancer treatment approach yields promising results in pediatric patients

Study shows GHRH antagonist's role in AML drug resistance

Study shows GHRH antagonist's role in AML drug resistance

Research identifies how leukemia develops resistance to first line treatments

Research identifies how leukemia develops resistance to first line treatments

Longer durations of breastfeeding lowers the risk of childhood cancers

Longer durations of breastfeeding lowers the risk of childhood cancers

ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells

ABT199/venetoclax synergism with thiotepa enhances cytotoxicity of chemo drugs in AML cells

Vitamin D shows promise in targeting aging's biological mechanisms, study finds

Vitamin D shows promise in targeting aging's biological mechanisms, study finds

Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplant

Rising survival rates for AML patients over 65 after allogeneic hematopoietic stem cell transplant

Groundbreaking atlas maps over 80 blood stem cell types

Groundbreaking atlas maps over 80 blood stem cell types

Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer

Concomitant pharmacotherapy overcomes immunotherapy challenges in aggressive blood cancer

The efficacy of the Mediterranean diet on health outcomes in adults with cancer

The efficacy of the Mediterranean diet on health outcomes in adults with cancer

Innovative therapy targets and destroys leukemia stem cells

Innovative therapy targets and destroys leukemia stem cells

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

CPRIT awards MD Anderson 16 grants to support cancer research and prevention

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

Novel approach improves CAR T-cell therapy efficacy against acute myeloid leukemia

Proteogenomics provides clues about drug response in acute myeloid leukemia

Proteogenomics provides clues about drug response in acute myeloid leukemia

Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

RBM5 identified as key regulator of HOXA9 in acute myeloid leukemia

Hidden identity of blood cancer revealed

Hidden identity of blood cancer revealed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.